NephroQuiz: muscles and bananas.
Published in Healthcare & Nursing, Genetics & Genomics, and General & Internal Medicine
A 40-year-old African American man arrived at the emergency room experiencing profound muscle weakness. Past medical history revealed sporadic muscle tightness occurring 1-3 times per week, alleviated by consuming bananas. He was not using any medications, and his family history was noteworthy for hyperthyroidism and episodes of hypokalemia in his brother and mother.
Upon presentation, vital signs were temperature 98.4°F, blood pressure 127/83 mmHg, heart rate 111 beats/minute, respiratory rate 11 breaths/ minute, and oxygen saturation 96% on room air. Physical examination revealed pronounced weakness in both upper and lower extremities (strength assessed at 0/5) with areflexia.
Laboratory results are shown in Table 1. The electrocardiogram demonstrated sinus tachycardia with prolonged QTc interval of 606 ms. Swift replacement of hypokalemia effectively alleviated his symptoms, albeit leading to transient hyperkalemia that spontaneously resolved.
|
|
||
|
Tests |
Results |
Normal range |
|
Sodium |
139 mmol/L |
132-148 mmol/L |
|
Potassium |
<1.5 mmol/L |
3.5-5 mmol/L |
|
Chloride |
105 mmol/L |
98-111 mmol/L |
|
Bicarbonate |
21 mmol/L |
23-32 mmol/L |
|
Blood Urea Nitrogen |
18 mg/dL |
10-25 mg/dL |
|
Creatinine |
0.91 mg/dL |
0.7-1.4 mg/dL |
|
Calcium |
9.3 mg/dL |
8.4-10.5 mg/dL |
|
Albumin |
3.9 g/dL |
3.5-5.0 g/dL |
|
Total protein |
7.2 g/dL |
6.6-8.7 g/dL |
|
Glucose |
90 mg/dL |
65-100 mg/dL |
|
Magnesium |
1.9 mg/dL |
1.6-2.6 mg/dL |
|
Phosphorus |
2.1 mg/dL |
2.5-4.5 mg/dL |
|
AST |
64 U/L |
5-40 U/L |
|
ALT |
153 U/L |
5-41 |
|
Bilirubin- total |
0.3 mg/dL |
0.2-1.2 mg/dL |
|
Alkaline phosphatase |
79 U/L |
40-129 U/L |
|
Random urine K/Cr ratio |
10.7 mmol/g Cr |
17-121 mmol/g Cr |
|
TSH |
< 0.006 mcIU/mL |
0.270-4.200 mcIU/mL |
|
Free T3 |
13.0 pg/mL |
2.1-4.4 pg/mL |
|
Free T4 |
3.04 ng/dL |
0.9-1.70 ng/dL |
|
Thyroid Stimulating Ig (TSI) |
3.43 IU/L |
<=0.54 IU/L |
|
Thyroid Peroxidase Ab |
62.6 IU/mL |
0.0-9.0 IU/mL |
The correct answer, link to published case and explanation will be provided in the comment section.
Click here to read the original case report, published in BMC Nephrology. We encourage discussion of the case and questions in the comments.
Follow the Topic
-
BMC Nephrology
This is an open access journal publishing original peer-reviewed research articles in all aspects of the prevention, diagnosis and management of kidney and associated disorders, as well as related molecular genetics, pathophysiology, and epidemiology.
Your space to connect: The Primary immunodeficiency disorders Hub
A new Communities’ space to connect, collaborate, and explore research on Clinical Medicine, Immunology, and Diseases!
Continue reading announcementRelated Collections
With Collections, you can get published faster and increase your visibility.
Vascular control and renal blood flow regulation
BMC Nephrology is calling for submissions to our Collection on Vascular control and renal blood flow regulation.
This Collection aims to explore the intricate relationships between vascular control and renal blood flow regulation, highlighting current research and advancements in this critical area.
Advances in the field have significantly enhanced our understanding of renal vascular dynamics and their implications for various kidney disorders, such as hypertension, chronic kidney disease, and acute kidney injury. Recent studies have focused on the molecular pathways involved in renal perfusion regulation, including the role of nitric oxide, prostaglandins, and endothelial function. By unraveling these complex interactions, researchers have begun to develop novel therapeutic strategies aimed at improving renal blood flow and preventing renal injury, thereby enhancing patient outcomes.
Future research in this domain holds promise for identifying new biomarkers and therapeutic targets that can lead to more effective interventions for renal diseases. As our understanding of renal circulation deepens, it is likely that innovative approaches will emerge, such as personalized medicine strategies that account for individual variations in renal vascular responses. Additionally, advancements in imaging techniques and computational modeling may provide unprecedented insights into renal blood flow regulation, facilitating better clinical decision-making.
Topics of interest include, but are not limited to:
Mechanisms of renal blood flow regulation
Impact of renal vascular dynamics on kidney disease
Role of endothelial function in renal perfusion
Advances in renal circulation imaging
This Collection supports and amplifies research related to SDG 3 (Good Health and Well-being).
All manuscripts submitted to this journal, including those submitted to collections and special issues, are assessed in line with our editorial policies and the journal’s peer review process. Reviewers and editors are required to declare competing interests and can be excluded from the peer review process if a competing interest exists.
Publishing Model: Open Access
Deadline: Mar 19, 2026
Novel therapies for glomerular diseases
BMC Nephrology invites submissions to our Collection on Novel therapies for glomerular diseases.
Glomerular diseases encompass a diverse group of disorders that affect the kidney's filtering units, leading to significant morbidity and mortality. These conditions, which include focal segmental glomerulosclerosis, minimal change disease, and IgA nephropathy, have traditionally posed challenges in terms of effective treatment options. Recent advancements in our understanding of the underlying pathophysiology and the introduction of novel therapeutic modalities, such as targeted biologics and small molecules, present new avenues for intervention. This Collection invites contributions that explore these innovative therapies and their potential to transform the management of glomerular diseases.
Advances in clinical research have led to promising developments, including the successful completion of several clinical trials that evaluate the efficacy of new agents. These therapies not only aim to improve patient outcomes but also focus on personalized treatment approaches that consider individual patient characteristics. By fostering collaboration among researchers, clinicians, and industry partners, we can enhance our understanding and management of these complex conditions. Continued research in this field has the potential to yield groundbreaking discoveries that could redefine treatment paradigms for glomerular diseases.
Topics of interest for this Collection include, but are not limited to:
Novel therapeutic agents in glomerular diseases
Clinical trials of innovative treatments
Impact of new therapies on patient outcomes
Personalized treatment approaches for glomerular disorders
This Collection supports and amplifies research related to SDG 3: Good Health and Well-being and SDG 9: Industry, Innovation, and Infrastructure.
All manuscripts submitted to this journal, including those submitted to collections and special issues, are assessed in line with our editorial policies and the journal’s peer review process. Reviewers and editors are required to declare competing interests and can be excluded from the peer review process if a competing interest exists.
Publishing Model: Open Access
Deadline: Jun 30, 2026
Please sign in or register for FREE
If you are a registered user on Research Communities by Springer Nature, please sign in
The correct answer is explained below:
.
.
.
.
.
The correct answer is: hypokalemic periodic paralysis.
Periodic paralysis (PP) is a rare channelopathy marked by recurrent episodes of flaccid skeletal muscle paralysis. Hypokalemic periodic paralysis (HypoPP) is categorized into familial or acquired forms. Triggers for episodes of HypoPP are primarily associated with intense exercise and high carbohydrate intake, and less frequently related to viral infections, stress, cold, salt consumption, and medications (such as glucocorticoids and insulin).
Familial HypoPP is associated with variants in the skeletal muscle sodium channel gene SCN4A in 20% of patients or the L-type calcium channel gene CACNA1S in 60% of patients. The majority of reported pathogenic variants involve arginine residues in S4 transmembrane segments, with notable hotspots at codons R528 and R1239. Generally, the existence of hyperthyroidism is more strongly associated with a diagnosis of acquired thyrotoxic periodic paralysis (TPP), with most cases occurring in Asian males without a family history of the condition. Pathogenic variants in KCNJ2 and KCNJ18 are associated with susceptibility to TPP. KCNJ2 and KCNJ18 encode Kir 2.1 and Kir2.6 respectively, inwardly rectifying potassium channels expressed in skeletal muscle and transcriptionally regulated by thyroid hormone.
Genetic testing in the discussed patient revealed a heterozygous pathogenic variant in CACNA1S [c.1583 G>A (p. R528H)] and normal sequencing of SCN4A, KCNJ2 and KCNJ18. The patient received a diagnosis of familial hypokalemic periodic paralysis and concurrent hyperthyroidism due to Graves’ disease. The likelihood of TPP in this case is reduced, given the patient is not of Asian descent, has a family history of HypoPP, and lacks identifiable variants in KCNJ2 and KCNJ18. The pathogenic variant observed in this case has been documented previously. This variant leads to a substantial reduction in the whole-cell calcium channel current and induces depolarization of the resting cell potential in response to hypokalemia.
Management of acute paralytic episodes involves maintaining proper control of serum potassium levels, necessitating vigilant monitoring for post-treatment hyperkalemia. Lifestyle and dietary modifications to avoid triggering factors are integral to treatment. Although the precise mechanism is not fully elucidated, carbonic anhydrase inhibitors have demonstrated efficacy in reducing the frequency of familiar HypoPP episodes. There is variability in the response to carbonic anhydrase inhibitors based on genotype; individuals with CACNA1S variants tend to exhibit a more favorable response compared to SCN4A variants. Additionally, the incorporation of a potassium-sparing diuretic, either in conjunction with carbonic anhydrase inhibitors or as a standalone treatment, may offer advantages for specific patients.
Read more in the published article: https://bmcnephrol.biomedcentral.com/articles/10.1186/s12882-024-03749-x
Read more in the published article: https://bmcnephrol.biomedcentral.com/articles/10.1186/s12882-024-03749-x